Together, we’re finding answers to cancer.

We co-ordinate cancer trials which are carried out in our network of 14 hospital based cancer trials research units across Ireland. These trials give participants early and free access to new cancer diagnostics and treatments.

Read more

New Videos

Impacts of Cancer Trials

Why Cancer Trials


16 January 2017 | In

Article on TNBC

Important article on triple negative breast cancer by Dr Fergus Keane and Dr Cathy Kelly just published in The Medical Independent. See here


Read more >

20 December 2016 | In

Merry Christmas

From all of us at Head Office and our colleagues in our 14 research units around the country, we wish you a merry and peaceful Christmas and New Year.

Read more >

19 December 2016 | In

Early stage breast cancer trial opens

50 Patients in Cork, Waterford and Dublin to get access to drug not yet approved in Ireland for early stage breast cancer

The Irish arm of a global cancer trial which will involve 4,600 patients in 500 hospitals around the world has been opened in Ireland by Cancer Trials Ireland and is looking for 50 Irish patients to take part.

The trial will investigate whether the new drug palbociclib will decrease the chance of cancer recurring in women and men with early stage HR positive /HER2 negative breast cancer when given in combination with the current standard anti-hormone therapy.

Known as the PALLAS trial it will be run in 6 hospitals in Ireland; Cork University Hospital, University Hospital Waterford, and in Dublin, Mater Hospital, Beaumont Hospital, St James’s Hospital and St Vincent’s University Hospital.

Patients interested in taking part in the trial should contact their Medical Oncologist.

Read more >

08 December 2016 | In

Trial confirms way to slow cancer

Dr Janice Walsh, Principal Investigator on the Paloma-2 trials discusses the results on RTE (13th December) HERE

An international cancer trial, in which Cancer Trials Ireland has had a lead role, has confirmed a treatment that can significantly reduce the risk of the cancer progressing in women with advanced breast cancer.

The PALOMA-2 trial confirmed that the new drug palbociclib taken with the standard hormone therapy letrozole slows the progress of cancer among postmenopausal women with advanced (ER-positive, HER2-negative) breast cancer.

The results of the trial have been published in the New England Journal of Medicine http://www.nejm.org/doi/full/10.1056/NEJMoa1607303.

Read more >

08 December 2016 | In

Big thanks

Cancer Trials Ireland has received a very generous donation of €7,760 towards its work on finding answers to cancer from family and friends of Ronnie Cox who sadly passed away six months ago. Before he died Ronnie organised a fundraiser with the Lough Conn Anglers for a charity to be selected by his oncologists Dr Ray McDermott. Dr McDermott, who is Vice Clinical Lead with Cancer Trials Ireland recommended Cancer Trials Ireland. We greatly appreciate the generosity of Ronnie’s family and friends and all who contributed to the fundraising effort, and particularly Ronnie himself. Ar dheis Dé go raibh a anam. 

Pictured at the presentation were (l to r) Gavin Cox, Rebecca Cox, Carmel Cox, Verena Murphy (Clinical Program Leader),  Eibhlin Mulroe (CEO), Ray McDermott (Vice Clinical Lead) along with Michael Monaghan and Eamon Ross representing the Lough Conn Anglers.


Read more >

06 December 2016 | In

RTE interview with CEO

Eibhlin Mulroe, CEO of Cancer Trials Ireland, featured on RTE 1’s The Business radio show last Saturday morning (3 December). You can listen back to the interview here http://www.rte.ie/radio/utils/radioplayer/rteradioweb.html#!rii=b9%5F21096812%5F172%5F03%2D12%2D2016%5F


Read more >

Answers to your questions about Cancer Trials.

Pharmaceutical Partners.

Cancer Trials Ireland has been conducting cancer trials with local and global pharmaceutical partners for many years.

We have a wealth of experience and expertise to deliver cancer trials success.

If you would like to find out more about how we can work together please contact: